Catrin Pritchard

Personal Details

Prof. Pritchard

Deputy Director of Leicester Cancer Research Centre

Tel: 0116 229 7061



  • 1983-1987: PhD at the Imperial Cancer Research Fund.
  • 1987-1990: Postdoctoral Fellow, University of California, San Francisco, USA.
  • 1991-1995: Postdoctoral Fellow, DNAX Research Institute, Palo Alto, California, USA.
  • 1995-2003: Royal Society Research University Research Fellow, University of Leicester.
  • 2003-2004: Lecturer, Department of Biochemistry, University of Leicester.
  • 2004-2009: Reader, Department of Biochemistry, University of Leicester.
  • 2009: Professor of Cancer Biochemistry, University of Leicester.
  • 2010-2015: Royal Society-Wolfson Research Merit Award Holder
  • 2014-2017: Science Director Cancer Research UK Leicester Centre
  • 2014-2018: Head of Leicester Cancer Research Centre, University of Leicester
  • 2018-present Deputy Director Cancer Research Centre, University of Leicester



Recent publications (since 2010)



Mechanisms of oncogene-driven tumour development

Our research is focussed on three areas:

  • Molecular characterisation of RAS and RAF conditional knockin mice in order to better understand cancer initiation and progression, focusing on lung adenocarcinoma and colorectal cancer models.
  • Investigation and manipulation of the tumour microenvironment in early disease models
  • Cholesterol metabolism in tumour associated macrophages (TAMs) and targeting of TAMs by cholesterol modulating agents.

Patient-derived explants (PDEs) for drug and biomarker discovery

We have optimised conditions for the ex vivo culture of fragments of human tumours as patient-derived explants (PDEs) without the requirement for tumour deconstruction. PDEs have the advantage over other preclinical models in that tumour architecture is retained intact, making them amenable to the testing of agents that target the tumour microenvironment including immune checkpoint inhibitors. We work with commercial organisations and translational charities to test the efficacy of novel anti-cancer agents in development and are applying digital pathology solutions at endpoint to identify and validate predictive and pharmacodynamic biomarkers. Our approach is being application to a wide range of human primary and metastatic cancers including breast, colorectal, lung, endometrial, renal cancers as well as melanoma and mesothelioma.


Share this page:


Powerful pre-clinical platform for anti-cancer drug and biomarker discovery

Pre-clinical models that can accurately predict outcomes in the clinic are much sort after in the field of cancer drug discovery and development.  Read about how patient derived explants offer many advantages and are the powerful model of choice. A copy of the review, published in the British Journal of Cancer, is available by clicking this link: PDE Platform


SEND Study Success

Congratulations to Chris Avery, who with collaborating colleagues published findings of the SEND study, a multi-centre randomised trial using two different surgical protocols for mouth cancer treatment.  A nationwide first for this type of trial, using real-world data.  The paper, published in the British Journal of Cancer, is available by clicking this link: SEND Paper


Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair

Contact Details

Leicester Cancer Research Centre
Robert Kilpatrick Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 


AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.